Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of AGN-151586 for moderate to severe glabellar lines in Japanese adults
jRCT2031230499Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2024
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of trenibotulinumtoxinE in glabellar furrowing (4 arms), sponsored by AbbVie Inc. Primary endpoint: At least 2-grade improvement on FWS-A at maximum frown through Day 7. Started Jan 2024; status: completed.
02
Drugs
trenibotulinumtoxinE
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on jRCT2031230499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230499.